Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.44 |
| ▸ | NPC1 | O15118 | 10/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9870201 | 0.84 | ALDH1A1 (0.35) | NPC1ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL6247283 | 0.79 | KDM4E (0.41) | RAB9ANPC1CYP1A2ALDH1A1KDM4E | |
| SCHEMBL29374931 | 0.78 | RAB9A (0.64) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL170196 | 0.78 | RAB9A (0.64) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL34463709 | 0.76 | RAB9A (0.61) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL31490600 | 0.76 | RAB9A (0.61) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL10866984 | 0.76 | RAB9A (0.61) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL31365172 | 0.76 | RAB9A (0.61) | RAB9ANPC1CYP3A4CYP1A2AR | |
| Hydrochloric Acid SCHEMBL31243061 | 0.76 | ALDH1A1 (0.63) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL30883993 | 0.76 | RAB9A (0.61) | RAB9ANPC1CYP3A4CYP1A2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649110-B1 | MYCOBACTERIUM-TUBERCOLOSIS-THIOREDOXIN REDUCTASE INHIBITOR AS ANTITUBERCULOSIS DRUG | UNIV DORTMUND TECH (DE) | 2021-09-08 | — | — | EP | claimed |
| EP-3652157-B1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2021-05-05 | — | — | EP | claimed |
| EP-3722284-A1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2020-10-14 | — | — | EP | claimed |
| EP-3402781-A1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2018-11-21 | — | — | EP | claimed |
| WO-2017121647-A1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-07-20 | — | — | WO | claimed |
| EP-2433937-B1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2016-06-29 | — | — | EP | claimed |
| US-20160151366-A1 | Compositions and Methods for Treating Autism Spectrum Disorders | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-06-02 | — | — | US | claimed |
| EP-2968322-A2 | MAP KINASE MODULATORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2016-01-20 | — | — | EP | claimed |
| US-9084794-B2 | Fatty acid synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2015-07-21 | — | — | US | claimed |
| EP-2086958-B1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2015-01-14 | — | — | EP | claimed |
| US-20040087650-A1 | Inhibitors of IMPDH enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2004-05-06 | — | — | US | claimed |
| US-20030232817-A1 | Small molecules useful for the treatment of inflammatory disease | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | claimed |
| EP-1355884-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| WO-2002060875-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-6313177-B1 | AS ANTIVIRAL AGENTS | PHARMACOR INC. (CA) | 2001-11-06 | — | — | US | claimed |
| CN-1056602-C | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-09-20 | — | — | CN | claimed |
| US-5939414-A | Benzodiazepine hydrazide derivatives as inhibitors of HIV integrase | MERCK & CO., INC. (US) | 1999-08-17 | — | — | US | claimed |
| US-5637729-A | AGRICULTURE | RHONE-POULENC AGROCHIMIE (FR) | 1997-06-10 | — | — | US | claimed |
| US-5270308-A | Hypotensives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-12-14 | — | — | US | claimed |
| EP-0010130-A1 | Sila-substituted 1,4-dihydropyridine derivatives, processes for their preparation, pharmaceutical compositions and process for their preparation | BAYER AG (DE) | 1980-04-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087650-A1 | Inhibitors of IMPDH enzyme | IMPDH1, IMPDH2, IMPA1 | RAB9A 2354/4885NPC1 417/4885CYP3A4 423/4885 |
| US-20030232817-A1 | Small molecules useful for the treatment of inflammatory disease | CD74, MSR1, SERPINB1 | RAB9A 2727/4885NPC1 760/4885CYP3A4 2868/4885 |
| US-20160151366-A1 | Compositions and Methods for Treating Autism Spectrum Disorders | GRIN2A, GRIN2C, NTRK2 | RAB9A 719/4885NPC1 409/4885CYP3A4 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.